<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630275</url>
  </required_header>
  <id_info>
    <org_study_id>Vitality1</org_study_id>
    <nct_id>NCT04630275</nct_id>
  </id_info>
  <brief_title>Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs</brief_title>
  <official_title>Vitality-Obs; An Observational and Descriptive Cross-sectional Study of Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Møller Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an observational cross-sectional study which aims to investigate the&#xD;
      relationship between treatment with chemotherapy and the development of low levels of&#xD;
      testosterone in the blood in patients cured for aggressive lymphoma. We hypothesize that&#xD;
      patients in turn will develop sexual dysfunction and poor quality of life because of this&#xD;
      reduced level of testosterone. Cancer treatment is increasingly effective and the overall&#xD;
      survival higher, which makes issues like sexuality and long-term quality of life more and&#xD;
      more important to address in cured cancer patients. Patient sexuality and quality of life is&#xD;
      measured by 3 questionnaires filled out once, and serum testosterone by a single blood&#xD;
      sample. We hope to show that future follow up visits should include focus on sexuality and&#xD;
      serum testosterone. Questionnaires and blood samples can be implemented easily and without&#xD;
      great cost.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffuse large B-cell lymphoma and Hodgkin Lymphoma are two aggressive lymphomas often treated&#xD;
      with doxorubicin containing chemotherapy. Doxorubicin is an anthracycline and is known to be&#xD;
      toxic to both Leydig Cells of the testes and hormone-producing cells of the hypothalamus.&#xD;
      Therefore patients treated with this drug are at risk of developing hypogonadism. Standard&#xD;
      follow-up programs do not include investigation of hormone levels. With this study we aim to&#xD;
      investigate the extent of hypogonadisme in patients treated with anthracycline containing&#xD;
      chemotherapy, to clarify whether it is relevant to include serum testosterone in standard&#xD;
      follow-up programs.&#xD;
&#xD;
      Our Hypothesis:&#xD;
&#xD;
      Hypothesis 1: A significant proportion of long-term male survivors of HL and DLBCL have&#xD;
      impaired QoL due to sexual dysfunction.&#xD;
&#xD;
      Hypothesis 2: A significant proportion of long-term male survivors of HL and DLBCL have&#xD;
      reduced levels of testosterone.&#xD;
&#xD;
      Hypothesis 3: A significant relationship between QoL, sexual dysfunction and testosterone&#xD;
      levels exists.&#xD;
&#xD;
      To clarify the extent of hypogonadisme a single blood test including s-total-testosterone&#xD;
      will be drawn once, and levels below 8nmol/L will be classified as hypogonadisme. To assess&#xD;
      patients sexuality and quality of life, 3 questionnaires will be filled out; the EORTC&#xD;
      QLQ-C30 for general quality of life, EORTC SHQ-22 for sexual health and IIEF-5 for sexual&#xD;
      function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum-testosterone level</measure>
    <time_frame>At inclusion</time_frame>
    <description>The frequency of sexual dysfunction measured by serum-testosterone level below 8 nmol/L, in patients with DLBCL or HL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of co-morbidity according to Cumulative Illness Rating Scale (CIRS) score</measure>
    <time_frame>At inclusion</time_frame>
    <description>The prevalence of CIRS score above 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Erectile Function according to International Index of Erectile Function (IIEF-5)</measure>
    <time_frame>At inclusion</time_frame>
    <description>The frequency of IIEF-5 scores below 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of sexual dysfunction symptoms</measure>
    <time_frame>At inclusion</time_frame>
    <description>According to SHQ-22 symptom scores. High symptoms scores represents high level of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of sexual function</measure>
    <time_frame>At inclusion</time_frame>
    <description>According to SHQ-22 function scores. High symptoms scores represents high level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Quality of life, functioning</measure>
    <time_frame>At inclusion</time_frame>
    <description>According to QLQ-C30 function scores. High function scores represents a high level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Quality of life, symptoms</measure>
    <time_frame>At inclusion</time_frame>
    <description>According to QLQ-C30 symptoms scores. High symptoms scores represents high level of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Quality of life, global health</measure>
    <time_frame>At inclusion</time_frame>
    <description>According to QLQ-C30 global health scores. High symptoms scores represents high level of global health.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypogonadism</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A cohort of patients with Hodgkin Lyphoma or Diffuse Large B-Cell Lymphoma diagnosed during&#xD;
        the period April 2008- April 2018 at the Departments of Hematology, Herlev Hospital,&#xD;
        Copenhagen University Hospital and Zealand University Hospital, will be identified through&#xD;
        The Danish Lymphoma registry (LyFo).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years at follow-up&#xD;
&#xD;
          2. Male&#xD;
&#xD;
          3. Verified diagnosis of de novo DLBCL or classical HL diagnosed between April 2008 and&#xD;
             April 2018 according to WHO classification.&#xD;
&#xD;
          4. Completed curative intent first line treatment with anthracycline-containing&#xD;
             chemotherapy with or without consolidating radiotherapy, with disease in complete&#xD;
             remission at EOT-PET/CT at least one year prior to inclusion.&#xD;
&#xD;
          5. Literate in Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent low-grade lymphoma&#xD;
&#xD;
          2. Current or prior lymphoproliferative disease of the central nervous system (CNS)&#xD;
&#xD;
          3. Current or prior lymphoproliferative disease of the testes&#xD;
&#xD;
          4. Mental or physical conditions that are expected to prevent the necessary &quot;compliance&quot;&#xD;
             and/or &quot;adherence&quot; in relation to the study procedures.&#xD;
&#xD;
          5. Treatment with second line chemotherapy or high dose therapy.&#xD;
&#xD;
          6. Current or prior anabolic steroid drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Will be based on social security number</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Signe Micas Pedersen, MD</last_name>
    <phone>+4542766462</phone>
    <email>signe.micas.pedersen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Møller Pedersen, MD</last_name>
    <phone>+4547324800</phone>
    <email>lmpn@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter De Nully Brown, MD</last_name>
      <phone>+4535451128</phone>
      <email>peter.brown@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jette Sønderskov Gørløv, MD</last_name>
      <phone>+4535458141</phone>
      <email>jette.goerloev@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Bjørn Poulsen, MD</last_name>
      <phone>+4547324809</phone>
      <email>cbpo@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Lars Møller Pedersen</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Hodgkin</keyword>
  <keyword>hypogonadism</keyword>
  <keyword>testosterone</keyword>
  <keyword>EORTC</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Sexuality</keyword>
  <keyword>Sexual health</keyword>
  <keyword>Cancer</keyword>
  <keyword>IIEF-5</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>anthracycline</keyword>
  <keyword>Leydig cells</keyword>
  <keyword>Hypothalamus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Gonadal Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

